US Stock MarketDetailed Quotes

Soleno Therapeutics(Delisted) (SLNO)

Watchlist
  • 53.010
  • 0.0000.00%
Close May 15 16:00 ET
2.76BMarket Cap27.47P/E (TTM)

About Soleno Therapeutics(Delisted) Company

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.

Company Profile

SymbolSLNO
Company NameSoleno Therapeutics(Delisted)
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees182
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Anish Bhatnagar, M.D.
  • President, Chief Executive Officer and Chairman of the Board
  • 51.16M
  • Meredith S. Manning
  • Chief Commercial Officer
  • 7.78M
  • Jennifer Fulk
  • Chief Financial Officer
  • --
  • Patricia C. Hirano
  • Senior Vice President, Regulatory Affairs
  • 6.05M
  • Kristen Yen
  • Senior Vice President, Global Clinical Operations and Patient Advocacy
  • --
  • Dr. Michael Huang, M.D.
  • Senior Vice President, Clinical Development
  • --
  • Dawn Carter Bir
  • Director
  • 673.92K
  • William G. Harris
  • Independent Director
  • 360.16K
  • Matthew Pauls, J.D.,M.B.A.
  • Lead Independent Director
  • 354.32K
  • Mark W. Hahn
  • Independent Director
  • --
  • Dr. Birgitte Volck, M.D.,PhD
  • Independent Director
  • 347.66K
  • Dr. Andrew Sinclair, PhD
  • Independent Director
  • 290.16K
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On June 3, Eastern Time, the U.S. House of Representatives passed a resolution limiting Trump's authority to use military force against Iran Show More